The Galien Forum USA 2019

October 24th 2019
Alexandria Center – New York City

 The Galien Forum, held every autumn at Alexandria Center for Life Science – New York, offers a full day of spirited discussions with Nobel Laureates, top policymakers, and leading industry executives who offer perspectives on the most significant health challenges of our time while highlighting the latest research and clinical pathways toward diagnosis, treatment, and cure.

PANEL 1

Digital Health – Orchestrating patient-centricity from molecule to market

7:45 am – 8:50 am

Panel Introduction    Register

Chair
MaryAnne Rizk
Senior Vice President Digital R&D Strategy
IQVIA

Panelists
Nancy Dreyer PhD, MPH, FISPE, Fellow DIA

Chief Scientific Officer
IQVIA

Emmanuel Fombu, MD, MBA
Physician, Award Winning Author;
Global Strategy and Digital Innovation Leader
Johnson & Johnson

Karl Hick
Chief Digital and Information Officer
Takeda

Jim Scholefield
Executive Vice President, Chief Information
and Digital Officer

Merck & Co.

Panelists bios

PANEL 2

Can disruptive innovation positively impact healthcare costs?

8:55 am – 10:00 am

Panel Introduction    Register

Co-Chairs
Joel S. Marcus
Executive Chairman & Founder
Alexandria Real
Estate Equities, Inc./
Alexandria Venture Investments;
Co-Founder
Alexandria Summit

Lynne Zydowsky, PhD
Chief Science Officer
Alexandria Real
Estate Equities, Inc./
Alexandria Venture Investments;
President and Co-Founder
Alexandria Summit

Panelists
David R. Epstein
Executive Partner
Flagship Pioneering

Joshua J. Ofman, MD, MSHS
Chief of Corporate Strategy
and External Affairs
GRAIL

David Schenkein, MD
General Partner, Google Ventures;
Executive Chairman of the Board & Former Chief Executive Officer,
Agios Pharmaceuticals

Panelists bios

PANEL 3

“Drugging the undruggable” with novel approaches to small molecule design

10:15 am – 11:20 am

In the journey of drug discovery and development, scientists are continually uncovering new pathways for treatment, often with a focus on either dialing up or dialing back the activity of a specific molecular target. Historically, this has involved identifying a protein that has a “druggable” binding pocket that can be targeted with a small molecule, or to design antibodies that bind to a specific known antigen.

Panel Introduction    Register

Chair
Mikael Dolsten
Chief Scientific Officer & President, Worldwide Research, Development and Medical (WRDM)
Pfizer

Panelists
Karin Briner
Vice President & Head, Global Discovery Chemistry
Novartis

Alessio Ciulli
Professor of Chemical & Structural Biology, School of Life Sciences
University of Dundee

Craig Crews
Founder and Chief Scientific Officer
Arvinas

Jennifer Petter
Chief Scientific Officer
Arrakis

Michael Ringel
Senior Partner & Managing Director
BCG

Panelists bios

PANEL 4

The marriage of technology and medicine: Bringing out the best in each other

11:25 am – 12:35 pm

Panel Introduction   Register

Chair
Bengt Samuelsson
Nobel Laureate
Former President,
Karolinska Institute
Former Chairman, Nobel Foundation

Panelists
Amy K. Butler, Ph.D.
Vice President & General Manager, Cell Biology
Thermo Fisher Scientific

Steve Rosenberg
Senior Vice President & General Manager
Oracle Health Sciences

Magnus Settergren
Assoc Prof and Interventional Cardiologist
Karolinska University Hospital and Karolinska Institute, Stockholm, Sweden

Eric Topol
Executive Vice President and Chair
Innovative Medicine Scripps Research;
Director & Founder
Scripps Research Translational Institute;
Author, Deep Learning

Panelists bios

PANEL 5

How will we be paying for medicine 10 years from now? (CEOs panel)

1:15 pm – 2:20  pm

Panel Introduction    Register

Co-Chairs
Susan Desmond-Hellmann
Chief Executive Officer
Bill & Melinda Gates Foundation
Prix Galien USA Committee Chair

Mike Rosenblatt
Chief Medical Officer
Flagship Pioneering

Panelists
Albert Bourla
Chief Executive Officer
Pfizer

Jacqualyn Fouse
Chief Executive Officer
Agios

Christophe Weber
Representative Director,
President & Chief Executive Officer
Takeda

Panelists bios

FIRESIDE CHAT

Delivering on the patient promise of gene therapy

02:25 pm – 03:15 pm

Register

* Panel introduction coming soon

Chair
Kathy High
President and Head of R&D
Spark Therapeutics

Panelists
Peter Marks
Director, Center for Biologics Evaluation and Research (CBER)
U.S. FDA

Maria Grazia Roncarolo
Director
Center for Definitive and Curative Medicine (invited)

Dr. Robin L. Smith
Founder
Neostem and Cura Foundation

Panelists bios

KEYNOTE

Keynote Dialogue: Innovation & Access

15:20 pm – 16:05 pm

Register

* Panel introduction coming soon

Susan Desmond-Hellmann
Chief Executive Officer
Bill & Melinda Gates Foundation
Prix Galien USA Committee Chair

Scott Gottlieb, MD
Former Commissioner
U.S. FDA